Online inquiry

IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8879MR)

This product GTTS-WQ8879MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets IFNA1; IFNB1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_024013.3; NM_002176.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439; 3456
UniProt ID P01562; P01574
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8879MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15480MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ6689MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ4634MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ12524MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ3540MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ5501MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ10263MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ1908MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGN 150998
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW